CTEV
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but negative book value makes traditional valuation impossible.
- Low P/S ratio
- Low Forward P/E
- Negative P/B ratio
- No Graham Number available due to negative earnings/equity
Growth is sluggish and earnings quality is extremely poor.
- Modest revenue growth (6.2%)
- Bullish analyst price targets
- Year-over-Year EPS growth of -174.2%
- Consistent failure to meet earnings estimates
Long-term trend is overwhelmingly bearish with significant value destruction.
- Recent 1-month recovery
- 5-year return of -91.9%
- History of massive earnings misses
Fundamental health is critical; company lacks a safety buffer for liabilities.
- Positive ROA (1.12%)
- Piotroski F-Score 2/9
- Current Ratio < 1.0
- Negative Equity
Non-dividend paying stock.
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CTEV and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CTEV
Claritev Corporation
Primary
|
-91.9% | -37.9% | +5.5% | -65.8% | +53.3% | +15.6% |
|
KIDS
OrthoPediatrics Corp.
Peer
|
-67.6% | -67.3% | -25.3% | -2.0% | -10.3% | -0.6% |
|
ENTA
Enanta Pharmaceuticals, Inc.
Peer
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
|
SRTA
Strata Critical Medical, Inc.
Peer
|
-54.4% | +64.4% | +74.4% | -8.4% | +6.0% | +13.1% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CTEV
Claritev Corporation
|
BEARISH | $403.98M | - | -% | -29.4% | $23.81 | |
|
KIDS
OrthoPediatrics Corp.
|
BEARISH | $403.7M | - | -11.3% | -16.8% | $15.97 | Compare |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | Compare |
|
SRTA
Strata Critical Medical, Inc.
|
BEARISH | $397.54M | - | -8.0% | 21.0% | $4.57 | Compare |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | ALBINSON BROCK | Officer | Stock Award | 2,956 | - |
| 2026-03-16 | GARIS DOUGLAS MICHAEL | Chief Financial Officer | Purchase | 1,300 | $22,997 |
| 2026-03-12 | KIM MICHAEL | Officer | Purchase | 15,000 | $247,500 |
| 2026-03-02 | O'NEIL TARA | General Counsel | Purchase | 750 | $9,742 |
| 2026-02-27 | ALBINSON BROCK | Officer | Stock Award | 23,243 | - |
| 2026-02-27 | KIM MICHAEL | Officer | Purchase | 30,000 | $428,955 |
| 2026-02-27 | KIM MICHAEL | Officer | Stock Award | 34,487 | - |
| 2026-02-27 | DALTON TRAVIS | Chief Executive Officer | Purchase | 15,380 | $199,928 |
| 2026-02-27 | DALTON TRAVIS | Chief Executive Officer | Stock Award | 278,925 | - |
| 2026-02-27 | CAROL NUTTER | Officer | Stock Award | 18,130 | - |
| 2026-02-27 | HOGGE JEROME | Chief Operating Officer | Stock Award | 66,322 | - |
| 2026-02-27 | GARIS DOUGLAS MICHAEL | Chief Financial Officer | Stock Award | 66,322 | - |
| 2026-02-27 | MINTZ WILLIAM B | Officer | Stock Award | 19,060 | - |
| 2026-02-27 | O'NEIL TARA | General Counsel | Stock Award | 18,130 | - |
| 2026-02-27 | MISENCIK TIFFANI | Officer | Stock Award | 26,342 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
CTEV utilizes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, and Adjusted EPS, to evaluate its core business performance. Investors should note that these metrics exclude critical cash requirements such as interest expenses, taxes, and capital expenditures, which may limit their utility as standalone analytical tools.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning CTEV from our newsroom.